What Is a 4-Panel Drug Test? Substances, Cutoffs & Use Cases

You've been asked to roll out a drug testing program for your organization, and the options are overwhelming. Five-panel, seven-panel, ten-panel, twelve-panel. Urine, oral fluid, hair. DOT-regulated, non-DOT. Then someone on your team mentions a 4-panel drug test (also called a four-panel drug screen), and you wonder: is that even enough? What does it cover, and when does it make sense? You're not alone in asking these questions. Drug testing is a massive, growing part of workplace safety, and choosing the right panel is one of the most consequential decisions an HR professional can make.

Disclaimer: This content is provided for informational purposes only and should not be construed as legal advice. Employers should consult qualified counsel for their specific situation.

This guide breaks down exactly what a 4-panel drug test is, what substances it screens for, how cutoff levels work, and where this particular panel fits into a smart, compliant employment screening strategy.

Key Takeaways

A 4-panel drug test screens for four specific substance categories, most commonly cocaine, amphetamines, opiates, and phencyclidine (PCP). Some configurations swap out one substance for another based on employer needs.

• Cutoff levels matter more than most HR teams realize. They're the thresholds that determine whether a specimen is reported as positive or negative, and they directly affect the reliability of your results.
• The 4-panel test is not a DOT-regulated panel. The Department of Transportation mandates a 5-panel test. A 4-panel test is a non-DOT option used by private employers who want a focused, cost-effective screen.
• "No-THC" 4-panel configurations are gaining traction as more states restrict employer use of marijuana test results in hiring decisions.
• Choosing the right panel is a compliance decision, not just a budget decision. Your industry, your state laws, and your workforce risk profile should all factor in.
• Partnering with a PBSA-accredited screening provider helps ensure your drug testing program stays compliant and your results are defensible.

Understanding the 4-Panel Drug Test

What It Covers

A 4-panel drug test analyzes a single specimen, most often urine, for the presence of four categories of controlled substances. Think of the "panel" number as the count of substance groups being tested. A 5-panel tests for five groups, a 10-panel tests for ten, and so on. The 4-panel sits at the leaner end of the spectrum, designed to detect the substances that pose the most common risks in a workplace setting without the broader scope (and higher cost) of larger panels.

How does it compare to other panels? The standard 5-panel, which is the federally mandated panel for DOT-regulated positions, screens for marijuana (THC), cocaine, amphetamines, opiates, and PCP. A 4-panel urine test typically drops one of those five substances. In many current configurations, THC is the substance removed, creating what's often called a "4-panel no-THC" or "4-panel minus marijuana" test. Other configurations may exclude PCP instead, depending on the employer's risk assessment and regional substance-use patterns.

Urine remains the most common specimen type for this panel, though oral fluid (saliva) testing is also available and growing in popularity. The choice of specimen type affects detection windows, collection logistics, and in some cases, applicable state laws.

Substances Detected

The most common configuration screens for these four substance categories:

• Cocaine (COC): This includes cocaine and its metabolite, benzoylecgonine. Cocaine is a Schedule II stimulant, and its presence in a workplace drug test is rarely attributable to legitimate medical use, though the MRO review process accounts for rare exceptions.
• Amphetamines (AMP): This category covers amphetamine and methamphetamine. It may also detect MDMA (ecstasy) depending on the assay used. Some prescription medications, such as those for ADHD, can trigger an initial positive, which is why confirmation testing and Medical Review Officer (MRO) review are critical.
• Opiates (OPI): Traditional opiate immunoassays detect morphine and codeine. Depending on the test's design and cutoff levels, it may also flag heroin use (through the presence of 6-acetylmorphine). Note that many synthetic and semi-synthetic opioids like oxycodone and fentanyl require expanded opiate testing and are not always captured in a standard opiate screen.
• Phencyclidine (PCP): PCP, also known as "angel dust," is a dissociative anesthetic. While its prevalence has declined in many regions, it remains on most standard panels because of the severe safety risks associated with its use.

The "No-THC" Configuration

For HR professionals operating across multiple states, this configuration addresses a real compliance pressure point. As of 2025, a growing number of states and municipalities have enacted laws that restrict or prohibit employers from taking adverse action based on a positive marijuana test result for certain positions. California, New York, New Jersey, Washington, and others have various protections in place. In response, many employers have shifted to a 4-panel configuration that excludes THC entirely, keeping the other four substances from the traditional 5-panel (cocaine, amphetamines, opiates, PCP) and removing the legal risk associated with marijuana screening in restricted jurisdictions.

This isn't about going soft on safety. It's about aligning your testing panel with the legal landscape you actually operate in.

The Lifecycle of a 4-Panel Drug Test

Selection and Implementation

Choosing a 4-panel test starts with your organization's risk profile. Identify which substances pose the greatest safety and productivity risk for your workforce, whether you're subject to federal or state testing mandates, and whether you operate in states with marijuana-related employment protections.

Consider the specific needs of your organization when selecting a panel. A 4-panel test may be the right fit for a tech company in a state with strong marijuana protections, while a transportation or manufacturing employer may need a broader panel or a DOT-compliant 5-panel. Your screening provider should help you evaluate these factors, not just hand you a menu.

Implementation involves more than picking a panel. You'll need a written drug testing policy that specifies when testing occurs (pre-employment, random, post-accident, reasonable suspicion), which panel is used, and what happens when a result comes back positive. That policy should be reviewed by legal counsel, especially if you operate across state lines.

Administration and Collection

The integrity of your results depends heavily on proper specimen collection. For a urine-based test, collection should follow established chain-of-custody procedures: using a certified collection site, having the donor provide the specimen under controlled conditions, sealing and labeling the specimen in the donor's presence, and maintaining documentation from collection through laboratory analysis.

Cutting corners here creates problems downstream. A broken chain of custody can render a positive result legally indefensible. Employers should work with collection networks that follow Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for federally regulated testing, or equivalent standards for non-DOT testing.

Oral fluid collection is an alternative that's gaining ground, particularly for reasonable-suspicion and post-accident testing where immediate, observed collection is advantageous. However, not all states permit oral fluid testing for employment purposes, so check your jurisdiction before making the switch.

Interpreting Results

A test result is not a simple pass/fail. The process involves two stages. First, an initial immunoassay screen. If that screen returns a presumptive positive, a confirmation test follows using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). Only results confirmed by the second, more specific method should be reported as positive.

After confirmation, results go to a Medical Review Officer (MRO), a licensed physician trained in substance abuse testing. The MRO contacts the donor to determine whether there is a legitimate medical explanation for the positive result, such as a valid prescription for an amphetamine-based ADHD medication. Only after the MRO's review is a final result reported to the employer.

This MRO step is not optional for a defensible program. It protects the donor's rights and protects your organization from acting on a result that has a legitimate medical explanation.

Understanding Cutoff Levels

Cutoff levels are the concentration thresholds, measured in nanograms per milliliter (ng/mL), that determine whether a specimen is reported as positive or negative. They exist for both the initial screen and the confirmation test, and the confirmation cutoff is typically lower than the screening cutoff.

SAMHSA publishes mandatory cutoff levels for federally regulated testing, and most non-DOT programs use the same or similar thresholds as a best practice.

Understanding cutoffs matters because they directly affect the sensitivity and specificity of your testing program. If you're evaluating a screening provider, ask them what cutoff levels they use and whether those levels align with SAMHSA guidelines.

4-Panel Drug Test Use Cases and Compliance Considerations

Employment Screening

The 4-panel drug screening is most commonly used by private-sector employers who are not subject to DOT or other federal testing mandates. It's a practical choice for organizations that want to maintain a drug-free workplace policy while keeping testing costs manageable and avoiding the legal complications that can come with marijuana testing in certain states.

Pre-employment testing is the most common application. A conditional offer of employment is extended, and the candidate completes the test as part of the background screening process. Beyond pre-employment, 4-panel tests are also used for random testing programs, post-accident testing, reasonable-suspicion testing, and return-to-duty testing. The panel itself doesn't change based on the testing occasion, but the legal requirements around when and how you can test may vary significantly by state.

DOT vs. Non-DOT: What HR Teams Need to Know

The Department of Transportation requires a specific 5-panel urine test for all safety-sensitive positions governed by DOT regulations, including commercial drivers, pilots, pipeline workers, and transit employees.

That 5-panel test must include marijuana. There is no DOT-approved 4-panel test. If your workforce includes DOT-regulated positions, those employees must be tested under the DOT protocol; there is no alternative panel that satisfies DOT requirements.

For everyone else, the non-DOT 4-panel test is a legitimate and increasingly popular option. But "non-DOT" doesn't mean "unregulated." State laws govern drug testing in the private sector, and they vary widely. Some states require employers to have a written policy before they can test. Others restrict testing to specific occasions. Several states now limit or prohibit adverse employment actions based on off-duty marijuana use or positive THC test results.

The challenge for multi-state employers: A 4-panel configuration that's perfectly compliant in Texas may need adjustment for employees in New York or California.

The solution: Working with a screening provider that has a counsel-led compliance team who tracks these changes and can flag issues before they become liabilities.

Emerging Trends in Drug Testing

Oral Fluid Testing

Oral fluid testing has matured significantly. Newer oral fluid assays offer improved sensitivity and broader detection capabilities, making them a viable alternative to urine for many non-DOT testing programs. The Substance Abuse and Mental Health Services Administration (SAMHSA): Federal workplace oral fluid testing guidelines signal broader acceptance of this specimen type.

Laboratory Technology Advances

On the laboratory side, advances in mass spectrometry have improved the accuracy and speed of confirmation testing. LC-MS/MS technology can now identify a wider range of substances and metabolites at lower concentrations, reducing the risk of both false positives and false negatives.

The Shift Toward THC-Free Panels

Looking ahead, the continued expansion of state-level marijuana legalization and employment protections will push more employers toward THC-free panels. The 4-panel no-THC configuration is likely to become even more common as employers balance safety concerns with legal compliance and talent acquisition realities. Expect to see greater integration between drug testing platforms and broader background screening technology, so HR teams can manage background checks, drug tests, and occupational health screenings from a single platform.

Actionable Steps for HR Professionals

• Audit your current drug testing panel against your legal obligations:  Review your existing panel in light of the states where you operate. If you're testing for THC in a state that restricts marijuana-based adverse actions, consult your employment counsel to assess whether this creates unnecessary legal exposure. If you have DOT-regulated positions, confirm those employees are on the mandated 5-panel, not a 4-panel.

• Develop or update your written drug testing policy: Your policy should specify the panel used, the testing occasions (pre-employment, random, post-accident, reasonable suspicion), the consequences of a positive result, and the MRO review process. Have it reviewed by employment counsel, especially if you operate in multiple states.

• Confirm your collection network follows chain-of-custody protocols: Ask your screening provider about their collection site network, their chain-of-custody procedures, and whether their sites follow SAMHSA-equivalent standards for non-DOT testing. A result is only as defensible as the process that produced it.

• Ensure MRO review is part of every positive result: Never take adverse action based on a preliminary positive or an unreviewed laboratory positive. The MRO review protects both the candidate and your organization.

• Evaluate whether a *"no-THC" 4-panel configuration makes sense for your workforce:  Talk to your legal counsel and your screening provider about whether removing THC from your panel aligns with your state laws, your industry requirements, and your safety needs.

• Ask your screening provider about cutoff levels: Understand what cutoff levels are being used for both the initial screen and the confirmation test, and confirm they align with SAMHSA guidelines or your organization's specific requirements.
• Plan for multi-state complexity now, not later: If your organization is growing into new states, build flexibility into your drug testing program from the start. A screening provider with a strong compliance infrastructure can help you adjust panels, policies, and procedures as your geographic footprint expands.

The AccuSourceHR Advantage

Drug testing compliance doesn't have to feel like guesswork. At AccuSourceHR, our team, trained in FCRA compliance, NDASA C-TPA Accredited, along with our counsel-led compliance group, works alongside your HR team to design a drug testing program that fits your industry, your state, and your risk profile. Whether you need a non-DOT 4-panel test, a DOT-compliant 5-panel, or an expanded panel with synthetic opioid coverage, we help you get it right from the start.

Our SourceDirect™ platform integrates drug testing orders with your broader background screening workflow, so your team manages everything in one place. And because we're backed by 100% US-based support. Calls are answered live and issues resolved within hours, so you're never left waiting when a question comes up mid-hiring process.

If your organization is working through drug testing panel decisions, multi-state compliance questions, or marijuana law changes, our team is ready to help. Share your thoughts on LinkedIn or contact our team to discuss your program.